Skip to main content
H

Hefei Lifeon Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 003020 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 749 across all filing types
Latest filing 2026-04-27 Notice of Dividend Amou…
Country CN China
Listing Shenzhen Stock Exchange 003020

About Hefei Lifeon Pharmaceutical Co., Ltd.

https://www.lifeon.cn

Hefei Lifeon Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and commercialization of pharmaceutical products. The company focuses on therapeutic areas including cardiovascular and cerebrovascular diseases, anti-infectives, and metabolic disorders. A key component of its portfolio is Clopidogrel Hydrogen Sulfate, an antiplatelet agent used for stroke and heart attack prevention. The organization operates advanced production facilities compliant with Good Manufacturing Practice (GMP) standards and maintains a strong commitment to technological innovation. Its research and development efforts are directed toward high-quality generic medications and the exploration of innovative drug delivery systems to address complex clinical requirements.

Recent filings

Filing Released Lang Actions
关于2025年度利润分配及资本公积金转增股本预案的公告
Notice of Dividend Amount Classification · 1% confidence The document is a regulatory “临时公告” detailing the company’s 2025 profit distribution plan: the cash dividend per 10 shares (RMB 3.00) and the capital reserve conversion into bonus shares (2 shares per 10). It is not a full annual report or audit report, nor a voting result notice, but rather an announcement of dividend payment details (including bonus share issues). Accordingly, it best fits the “Notice of Dividend Amount” category (DIV).
2026-04-27 Chinese
2026年一季度报告
Interim / Quarterly Report Q1 2026
2026-04-27 Chinese
非经营性资金占用及其他关联资金往来情况专项说明
Audit Report / Information Classification · 1% confidence The document is a special audit report issued by Zhonghui CPA firm on non-operating fund usage and related party transactions for Hefei Lifang Pharmaceutical Co., Ltd. It includes management and auditor responsibilities, scope, and a special audit opinion, followed by audited summary tables. This is a standalone audit report and not a full annual or interim report. It matches the definition of an Audit Report / Information (AR).
2026-04-27 Chinese
关于聘请2026年度财务审计机构的公告
Regulatory Filings Classification · 1% confidence The document is a formal public announcement by a listed company regarding the proposed appointment (re-appointment) of its external auditor for the next fiscal year. It does not itself contain an audit report (AR), nor is it a financial report (10-K, IR) or proxy/material for shareholder voting (PSI). It is not a board or management change announcement (MANG) since it concerns auditor engagement, and it is not covered by any other more specific category. Therefore, under the fallback “Regulatory Filings” category, the correct classification is RNS.
2026-04-27 Chinese
2025年度独立董事述职报告-史静
Governance Information Classification · 1% confidence The document is a standalone "Independent Director’s Performance Report" (独立董事述职报告) for the 2025 year, detailing the director’s duties, attendance at board and committee meetings, key governance oversight activities, and compliance with regulatory governance requirements. It is not announcing or publishing an attached report nor is it a financial or earnings document. Instead, it directly concerns corporate governance practices, board structure, and the director’s performance of governance duties. Therefore, the best matching category is Governance Information (CGR).
2026-04-27 Chinese
2025年度内部控制评价报告
Audit Report / Information Classification · 1% confidence The document is titled '2025年度内部控制评价报告' (2025 Internal Control Evaluation Report) issued by the company’s board and audit committee, detailing the scope, standards, procedures, findings, and conclusions regarding the effectiveness of internal controls over financial and non-financial reporting. It is a standalone internal control evaluation report, not an annual or interim financial report, nor a simple announcement or presentation. This type of document falls under standalone audit/internal control reporting.
2026-04-27 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.